EBSCO Logo
Connecting you to content on EBSCOhost
Results
Title

A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection.

Authors

Counoupas, Claudio; Johansen, Matt D.; Stella, Alberto O.; Nguyen, Duc H.; Ferguson, Angela L.; Aggarwal, Anupriya; Bhattacharyya, Nayan D.; Grey, Alice; Hutchings, Owen; Patel, Karishma; Siddiquee, Rezwan; Stewart, Erica L.; Feng, Carl G.; Hansbro, Nicole G.; Palendira, Umaimainthan; Steain, Megan C.; Saunders, Bernadette M.; Low, Jason K. K.; Mackay, Joel P.; Kelleher, Anthony D.

Abstract

Global control of COVID-19 requires broadly accessible vaccines that are effective against SARS-CoV-2 variants. In this report, we exploit the immunostimulatory properties of bacille Calmette-Guérin (BCG), the existing tuberculosis vaccine, to deliver a vaccination regimen with potent SARS-CoV-2-specific protective immunity. Combination of BCG with a stabilised, trimeric form of SARS-CoV-2 spike antigen promoted rapid development of virus-specific IgG antibodies in the blood of vaccinated mice, that was further augmented by the addition of alum. This vaccine formulation, BCG:CoVac, induced high-titre SARS-CoV-2 neutralising antibodies (NAbs) and Th1-biased cytokine release by vaccine-specific T cells, which correlated with the early emergence of T follicular helper cells in local lymph nodes and heightened levels of antigen-specific plasma B cells after vaccination. Vaccination of K18-hACE2 mice with a single dose of BCG:CoVac almost completely abrogated disease after SARS-CoV-2 challenge, with minimal inflammation and no detectable virus in the lungs of infected animals. Boosting BCG:CoVac-primed mice with a heterologous vaccine further increased SARS-CoV-2-specific antibody responses, which effectively neutralised B.1.1.7 and B.1.351 SARS-CoV-2 variants of concern. These findings demonstrate the potential for BCG-based vaccination to protect against major SARS-CoV-2 variants circulating globally.

Subjects

COVID-19 vaccines; SARS-CoV-2; COVID-19 pandemic; IMMUNITY; ANTIBODY formation; IMMUNOGLOBULIN G; T helper cells

Publication

NPJ Vaccines, 2021, Vol 6, Issue 1, p1

ISSN

2059-0105

Publication type

Academic Journal

DOI

10.1038/s41541-021-00406-4

EBSCO Connect | Privacy policy | Terms of use | Copyright | Manage my cookies
Journals | Subjects | Sitemap
© 2025 EBSCO Industries, Inc. All rights reserved